Dyadic International Inc. Corona-Impfstoff der Isreali - Forscher in der Pipeline? - 500 Beiträge pro Seite

[Mike-Foxtrott]

Dyadic International Inc. kooperiert mit dem "Israel Institute for Biological Resarch"

Hier die Meldung vom 25.Februar:

https://www.quotemedia.com/portal/news?qm_symbol=DYAI



Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.
IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).
The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform known to shorten the development cycle, lower the manufacturing cost and improve the performance of vaccines and mAbs.
"Our collaboration with the IIBR is aimed at finding additional solutions to combat the COVID-19 coronavirus outbreak that threathens the lives of people in China and globally," commented Mark A. Emalfarb, Founder and CEO of Dyadic. "There is a global need to apply new platforms and technologies that will facilitate a fast, coordinated and practical response to new infectious diseases during pandemic and epidemic outbreaks or a bioterrorist attack and we believe that Dyadic's C1 technology is well-positioned to contribute to this global effort."
"Certain data and results generated from this collaboration are expected to futher validate the versatility and safety of our C1 gene expression platform," said Dr. Ronen Tchelet, Dyadic's Chief Scientific Officer.
"The Israel Institute for Biologcal Research was assigned by the Israeli Prime minister, Mr. Benjamin Netanyahu, to act as quickly as possible to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19," said Prof. Shmuel C. Shapira, Director General of IIBR. Prof Shapira continued, "More than 50 experienced Ph.D. IIBR's scientists are working tirelessly to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19. This is a world-leading group in aspect of knowledge, experience and infrastructure. The Israel Institute for biological research was assigned to the task based on its proven professional scientific capabilities and previous successes in the field."
About Israel Institute for Biological Research
The Israel Institute for Biological Research (IIBR) is a national center for research and development that specializes in the fields of biology, chemistry and the environmental sciences, and aims to enhance Israel's strengths and fortitude. IIBR recruits leading Israeli scientists and benefits from cutting edge technologies and infrastructure built to serve the topmost research and strict safety standards. IIBR capabilities, scientific achievements and decades of advanced R&D lead to national and international reputation and prestigious collaborations.

Hier die Web-Seite des Institutes:

https://iibr.gov.il/Pages/home.aspx

Hier die Web-Seite von Dyadic:

https://www.dyadic.com/


Es gab am Freitag den 28.Februar diesen Bericht auf FOX News, wo der CEO interviewt wird:

https://www.foxbusiness.com/healthcare/coronavirus-vaccine-a…

Die Israelis sollen laut diesem Bericht 50 Wissenschaftler auf Hochtouren am Arbeiten haben...um einen schnellen Corona Impfstoff zu entwickel.

Er soll evtl. schon in 2 bis 3 Monaten bereit sein...um dann von Dyadic in Massen produziert werden zu können!

Hört sich m.M. recht spannend an.
... bin hier eingestiegen.

[Mike-Foxtrott]

Antwort auf Beitrag Nr.: 62.854.641 von Mike-Foxtrott am 02.03.20 17:41:52

Hier die Finanzdaten auf ADVFN: (die WO-Angabe ist immer noch von Freitag)

https://de.advfn.com/borse/NASDAQ/DYAI/kurs

[pischtie_hufnagel]

Dyadic International Appoints New Board Member


https://finance.yahoo.com/news/dyadic-international-appoints…

[pischtie_hufnagel]

Jan 2021 Dyadic Investor Presentation

[pischtie_hufnagel]

ECI Microbial Engineering January 2021


https://www.dyadic.com/wp-content/uploads/2021/01/ECI-Microb…

[pischtie_hufnagel]

Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors


https://finance.yahoo.com/news/dyadic-enters-collaboration-t…

[pischtie_hufnagel]

Dyadic to Present at ZAPI Stakeholders Virtual Meeting


https://irdirect.net/prviewer/release_only/id/4612913

[pischtie_hufnagel]

Antwort auf Beitrag Nr.: 66.800.623 von pischtie_hufnagel am 03.02.21 16:44:23

About ZAPI: https://zapi-imi.eu

[pischtie_hufnagel]

DYAI Adds TurtleTree To Its Stable


https://finance.yahoo.com/news/dyai-adds-turtletree-stable-1…

[pischtie_hufnagel]

28th International Molecular: Med Tri-Con Virtual Conference & Expo


"COVID-19 Vaccines & Biotherapeutics"
Presenter: David A. Zarling PhD, MBA
"SARS-CoV-2 Variants: MultiValent Antigen Vaccines & COVID-19 Monoclonal Antibody Therapeutics"
Date: Wednesday, February 17, 2021
Time: 5:00 PM (ET), Panel Discussion Immediately Following

https://www.triconference.com/covid-vaccines

[pischtie_hufnagel]

2021 BIO CEO & Investor Digital Conference


https://www.dyadic.com/wp-content/uploads/2021/02/BIO-CEO-In…

[pischtie_hufnagel]

28th Int'l Molecular: Med Tri-Con Virtual Conference & Expo"COVID-19 Vaccines & Biotherapeutics"

[pischtie_hufnagel]

[pischtie_hufnagel]

[pischtie_hufnagel]

Dyadic CEO Mark Emalfarb presents at H.C. Wainwright Global Life Sciences Conference

[pischtie_hufnagel]

Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting



https://finance.yahoo.com/news/dyadic-announces-scientific-a…

[pischtie_hufnagel]

Dyadic CEO Mark Emalfarb presents at 33rd Annual Roth Conference

[pischtie_hufnagel]

CEO ROUNDTABLE WuXi Healthcare Forum 2021


https://www.wuxionline.com/WHF2021/index.html#/roundDetail?…

[pischtie_hufnagel]

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100



https://finance.yahoo.com/news/dyadic-advancing-towards-h…

[pischtie_hufnagel]

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants


https://finance.yahoo.com/news/dyadic-medytox-develop-vaccin…

[pischtie_hufnagel]

A new, pan-virus methodology for ramping up vaccine production
ZAPI have put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis


https://www.imi.europa.eu/news-events/newsroom/recipe-next-d…

[pischtie_hufnagel]

CEO’s Presenting on the Emerging Growth Conference on March 31.

12:15 – 1:00
Dyadic International, Inc. (NASDAQ: DYAI)
Mark Emalfarb, President / CEO presenting

We may see some schedule changes on Wednesday. To stay current on the schedule, please follow us on Twitter: https://twitter.com/EmergingGrowthC

[pischtie_hufnagel]

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial




https://finance.yahoo.com/news/dyadic-advancing-proprietary-…

[pischtie_hufnagel]

Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results



Conference Call Information

Date: Tuesday, March 30, 2021
Time: 5:00 p.m. Eastern Time

Webcast Link: https://www.webcaster4.com/Webcast/Page/2031/40394

[pischtie_hufnagel]

Dyadic Reports 2020 Year End Results and Recent Company Progress


- Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial

- To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization

- To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates

- Expanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boosters

- In parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under development

- Developing anumber of other infectious disease vaccines and antibodies internally and in conjunction with others

- Expanding commercial opportunities of C1 technology through eleven new and two expanded collaborations for human and animal health applications

- C1 selected by ZAPI (Zoonosis Anticipation Preparedness Initiative) as a vaccine manufacturing platform for more efficient production of antigens that are safe, effective, and protective

- Cash and investment grade securities of $29.2 million at year-end 2020




https://www.accesswire.com/viewarticle.aspx?id=638231

[pischtie_hufnagel]

How Dyadic International Inc Fits into the Vaccine 2.0 Gold Rush



https://www.wallstreetpr.com/how-dyadic-international-inc-na…

[pischtie_hufnagel]

DYAI: Headed to the Clinic





https://finance.yahoo.com/news/dyai-headed-clinic-095100401.…

[pischtie_hufnagel]

Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations?


https://otcprwire.com/is-dyadic-international-inc-nasdaq-…

[pischtie_hufnagel]

Dyadic announces development of COVID-19 Vaccine in India



https://finance.yahoo.com/news/dyadic-announces-development-…

[pischtie_hufnagel]

Dyadic Presents at BIO Digital 2021

[pischtie_hufnagel]

Dyadic Presents at BIO Digital 2021

[pischtie_hufnagel]

Dyadic CEO Mark Emalfarb Presents at AVMI

[pischtie_hufnagel]

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries

Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement

Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials

Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100

Intends to reduce African dependence on foreign vaccine suppliers

Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population


...
https://finance.yahoo.com/news/dyadic-announces-technology-t…

[pischtie_hufnagel]

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic’s lead COVID-19 vaccine candidate.

Dyadic’s lead COVID-19 Vaccine, DYAI-100, utilizes the SARS-CoV-2 Spike Protein receptor binding domain (RBD) and has been extensively studied in vitro and in vivo for its induction of high-titer neutralization activities in vaccinated animals against the SARS-CoV-2 virus and its major variants of concern (VoCs).

MultiValent COVID-19 Vaccine is under development using the RBDs for the VoCs, such as delta, alpha, beta, gamma and lambda, and is designed to cover all known and emerging VoCs.

Consideration includes a $10 million upfront payment ($5 million in cash and $5 million in Sorrento stock), reimbursement of certain DYAI-100 R&D expenses, with potential for multiple future development milestones and royalty payments.

.....
...
..

https://finance.yahoo.com/news/sorrento-dyadic-announce-bind…

[pischtie_hufnagel]

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate

New collaboration with India's Syngene International to develop a COVID-19 vaccine candidate

New co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100

Potential to support vaccine production for up to 100% of the world's population

Dyadic's C1 production platform utilized in ZAPI study published in "VACCINES," a leading peer-reviewed scientific journal

Sale of equity interests in BDI Holdings and VLP Bio realizing 1.3 million euros in cash and approximately 30% ROI

66.5% year over year revenue increase

Cash and investment grade securities of $25.8 million as of June 30, 2021

.....

...

..


https://finance.yahoo.com/news/dyadic-reports-second-quarter…

[pischtie_hufnagel]

Dyadic Presents at H.C. Wainwright 23rd Annual Global Investment Conference

[pischtie_hufnagel]

Dyadic Presents at BioProcess International 2021 - Cell & Gene Therapy Mfg & Commercialization US

[pischtie_hufnagel]

Benzinga Healthcare Small Cap Conference

ab 3:13:00 DYADIC CEO
ab 3:31:30 Diskurs

[pischtie_hufnagel]

Form 8-K

Item 7.01 Regulation FD Disclosure

Sorrento Therapeutics, Inc. (?Sorrento?) and Dyadic International (USA), Inc. (?Dyadic?) have not executed the License Agreement within the forty-five business day time period set forth in the Term Sheet For Intellectual Property License Agreement by and between Sorrento and Dyadic, dated August 10, 2021 (the ?Term Sheet?). The parties are continuing to discuss and negotiate certain matters relating to certain provisions of the License Agreement. Unless and until the open matters are resolved, Dyadic can give no guidance if or when the License Agreement will be executed. In the interim, other activities, including technology transfer to Sorrento relating to DYAI-100 and C1, will continue under the provisions of the Term Sheet, which is binding on both parties and which continues until the execution of the License Agreement.


https://fintel.io/doc/sec-dyadic-international-inc-1213809-8…

[pischtie_hufnagel]

Dyadic Appoints Chief Business Officer to Executive Leadership Team

https://finance.yahoo.com/news/dyadic-appoints-chief-busines…

[pischtie_hufnagel]

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

● COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption

● Five non-COVID-19 infectious disease monoclonal antibody and antigen development programs are ongoing

● Animal health vaccine project continues to demonstrate safety and efficacy advancing towards potential commercialization

● Entered two new fully funded R&D collaborations with academia and industry

● Executive leadership team enhanced with the appointment of Joseph Hazelton, Chief Business Officer

● Received $1.6M in cash from sale of equity interest in BDI

● Licensing Agreement discussions continue with Sorrento Therapeutics; technology transfer initiated

● Cash and investment grade securities of $22.8 million as of September 30, 2021


....

https://finance.yahoo.com/news/dyadic-reports-third-quarter-…

[pischtie_hufnagel]

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call Transcript

https://seekingalpha.com/article/4468254-dyadic-internationa…

[pischtie_hufnagel]

C1 Technology Platform Rapid response to Pandemic and other biological threats Support the global combat against SARS-CoV-2 Variants of Concern November 2021

https://www.dyadic.com/wp-content/uploads/2021/11/C1-Technol…

[pischtie_hufnagel]

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, announced that it has entered into a Research, License and Collaboration Agreement (“Agreement”) with Janssen Biotech, Inc. (‘’Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the Agreement:

Janssen will pay Dyadic an upfront payment of $500,000 for non-exclusive rights to utilize the C1 platform to develop C1 production cell lines for the manufacturing of Janssen’s therapeutic protein candidates against several biologic targets.

Janssen will provide R&D funding up to €1.6 million to develop and assess C1 production cell lines for its product candidates.

Janssen has the option to pay a mid-seven figure payment for an exclusive license from Dyadic to use the C1 platform for the manufacturing of therapeutic proteins directed to one specific target.

Further, Janssen has an option to obtain the following rights from Dyadic.

Upon exercise of the option, Dyadic would receive a milestone payment in the mid-seven figures and Janssen would have the right to add additional non-exclusive targets to the collaboration.

Dyadic would complete C1 platform technology transfer, fully enabling Janssen to internally develop C1 cell lines against licensed targets; upon successful completion of technology transfer, Dyadic is eligible to receive a milestone payment in the low seven figures.

For each product candidate, Dyadic could receive development and regulatory milestones in the mid-seven figures.

Dyadic could receive commercial milestone payments in the low nine figures per product, subject to a limit on the number of such products. The amount will depend on the cumulative amount of active pharmaceutical ingredient produced by Janssen for each product manufactured with Dyadic’s C1 platform.
“We are excited to announce this strategic partnership with Janssen using our C1-cell protein production platform. We continue to expand our partnerships across a growing number of therapeutic areas, and we continue to believe in the broad utility of Dyadic’s C1 technology,” said Mark Emalfarb, Dyadic's President and Chief Executive Officer.


https://finance.yahoo.com/news/dyadic-announces-research-lic…

[pischtie_hufnagel]

Dyadic International (NASDAQ:DYAI) Earns Buy Rating from Analysts at HC Wainwright

Analysts at HC Wainwright started coverage on shares of Dyadic International in a note issued to investors on Friday, Briefing.com reports. The brokerage set a "buy" rating and a $7.00 price target on the biotechnology company's stock. HC Wainwright's price objective would suggest a potential upside of 77.22% from the stock's previous close.


https://www.marketbeat.com/instant-alerts/nasdaq-dyai-a-buy-…

[pischtie_hufnagel]

https://twitter.com/yahoofinance/status/1476652956690886666?…

[pischtie_hufnagel]

Investor-Presentation-January-2022

https://www.dyadic.com/wp-content/uploads/2022/01/Investor-P…

[pischtie_hufnagel]

Dyadic Presents at H.C. Wainwright Bioconnect Conference

[pischtie_hufnagel]

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs, while enhancing commercial scales to improve access to biologic products in animal and human health, today announced its industrially proven C1-cells have been engineered to demonstrate the potential to manufacture therapeutically viable and commercially useful cannabis compounds including cannabidiol (CBD) and its precursors using synthetic biology. C1-cells have the potential to be an easy way to produce pure synthetic cannabinoids for commercial use cheaper and more effectively as compared to conventional extraction methods utilizing hemp and the marijuana plant, Cannabis sativa.

“For the consumer, the potential benefits are high-quality, low-cost CBD, other forms of cannabinoids and THC. You can get exactly what you want from the C1-cells,” said Dr. Ronen Tchelet, Dyadic’s Chief Scientific Officer. Dr. Tchelet continued, “Filamentous fungal cell factories are expected to be more environmentally friendly and less energy intensive than growing the plant and separating out the psychoactive and non-psychoactive ingredients. They may also yield cannabinoid derivatives with unexpected medical uses. Interest in CBD and other forms of cannabinoids has widened as earlier studies have demonstrated the bioactive effects of CBD in animals and humans through numerous CBD receptor pathways. In particular, in the immune system which has demonstrated mediating therapeutic effects related to inflammation in animal models. Cannabinoids and preparations of Cannabis material have recently found application as therapeutics for chronic pain, multiple sclerosis, cancer-associated nausea and vomiting, weight loss, appetite loss, spasticity, and other conditions. It has recently been reported that two cannabinoid acids, CBGA and CBDA, commonly found in hemp varieties of cannabis can bind to the spike protein of coronavirus which may help to prevent infection of human cells. The study also reported that cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. The study from which these findings were derived was conducted in collaboration with scientists at the Oregon Health & Science University and recently published by the 'Journal of Natural Products.'”

While synthetic cannabinoid compounds have been approved by the FDA, the chemical synthesis is relatively costly, and can involve the use of chemicals that are not environmentally friendly, and, most importantly, various chemically synthesized cannabinoids have been classified as less pharmacologically active as those extracted from plants such as the sativa strain of cannabis.

Dyadic’s synthetic biology cannabinoid C1 production process has the potential to develop commercially viable biological methods of producing CBD, such as cannabigerolic acid (CBGA), cannabigerovarinic acid (CBGVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabidivarinic acid (CBDVA) and uses thereof for producing said precursors and cannabinoids.

“We are excited to introduce a novel synthetic production method of producing CBD and precursor molecules from filamentous fungi. As with other commercially proven applications which have been improved using Dyadic’s C1 production platform, there are potential distinct advantages over naturally extracting CBD and other cannabinoids from plants. We believe the Company’s C1 production platform can be used to produce a purer, regulatory compliant end product that is not only economical, but more environmentally friendly as compared to conventional plant derived cannabinoid production processes. We also believe that by using synthetic biology to further engineer and optimize the production of C1-cells to produce CBD, other cannabinoids and THC will generate great interest in light of the burgeoning potential uses for CBD and other cannabinoids in animal and human health, including medical and recreational marijuana and cannabinoid products, such as CBD,” said Mr. Emalfarb, Dyadic’s Chief Executive Officer.

“Our decision to engineer C1-cells for the production of CBD and other cannabinoids is part of the Company’s synthetic biology programs, and as part of Dyadic’s 2022 strategic operating plan, we are focused across three core business verticals: (i) human health with a focus on infectious disease, including COVID-19, (ii) noninfectious diseases in human and animal health, and (iii) other biological products including enzymes and metabolites,” said Joe Hazelton, Dyadic’s Chief Business Officer. “Additionally, as we look at the year ahead, Dyadic intends to further advance and develop our pipeline of assets, both internally and through joint ventures, licensing, partnerships, and other collaborations,” concluded Mr. Hazelton.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company that is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing, which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.



https://www.globenewswire.com/news-release/2022/01/20/237017…

[pischtie_hufnagel]

A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice

https://www.sciencedirect.com/science/article/pii/S0264410X2…

[pischtie_hufnagel]

The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines

https://www.mdpi.com/2076-393X/10/2/148

[pischtie_hufnagel]

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.

JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, and Phibro Animal Health ("Phibro") (NASDAQ: PAHC), a leading global diversified animal health and mineral nutrition company, jointly announced that they have entered into an exclusive license agreement for a Phibro targeted disease. This agreement follows the successful proof of concept development work, including animal trials, which was previously completed by the two companies.

Under the terms of the Agreement:

Dyadic granted Phibro an exclusive license for its proprietary C1 -cell protein production platform to produce specific targeted antigens for development and commercialization of a poultry vaccine for a Phibro targeted disease.
The parties will continue development work to find a vaccine candidate using Dyadic's C1 cells.
The parties expect to continue working on developing additional animal vaccine candidates to be produced from Dyadic's C1-cells.
"Phibro has been excellent to work with on this project and we look forward to expanding our collaboration to develop more cost-efficient, high-performance animal vaccines that can be produced from our proprietary and patented C1-cell protein production platform. Animal health continues to be a core market for Dyadic, where the broad utility of C1 engineered cell lines have the potential to significantly reshape how animal vaccines are brought to market and manufactured in terms of speed, scale, cost and manufacturing time," said Mark Emalfarb, Dyadic's President and Chief Executive Officer.

Avner Finger, Phibro's Vice President of Research and Development commented, "Following the successful animal testing of antigens produced by Dyadic's C1 expression system for a targeted disease, we are pleased to be moving into the next stage of development to produce a viable vaccine candidate. Phibro remains committed to innovation and supplying superior animal health vaccines and feed solutions. Our commitment extends to not only consumers but to the ethical global supply chain of farmers and animals under their care, in order to provide a healthy source of protein."

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please visit www.pahc.com.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com